SecBot SecBot
SECBOTREPLAY Home › Report › PHIO

PHIO · Phio Pharmaceuticals announced a key development milestone for its lead…

Phio Pharmaceuticals Corp. · 8-K filed Sep 14, 2026 at 08:59 ET

At the news

BULLISHIMPACT 5/10

8-K filed Sep 14, 2026 at 08:59 ET

Phio Pharmaceuticals announced a key development milestone for its lead siRNA candidate PH-762, submitting a meeting request and comprehensive briefing package to the FDA to support a planned Phase 2b neoadjuvant study in cutaneous squamous cell carcinoma, following the formal completion of the Phase 1b trial. Clinical supplies for the next study are expected in Q1 2027, and the nonclinical toxicology dosing phase has been completed. This is an early-stage regulatory step with no financial data or clinical results disclosed, making it a modestly positive but highly uncertain catalyst for a $12M market cap pre-revenue biotech.

  • Phio submitted a meeting request and comprehensive briefing package to the FDA for PH-762 in cutaneous squamous cell carcinoma.
  • The submission follows the formal completion of the Phase 1b trial and supports a planned Phase 2b neoadjuvant study.
  • Clinical supplies for the next planned study are expected to be available in Q1 2027.
  • The dosing phase of the nonclinical toxicology study has been completed.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access